Search Results

A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

• Source: A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma,

Record details

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment (LocoMMotion)

• Authors : Legend Biotech

• Source: A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI,

Record details

Biosynthesis of lactacystin as a proteasome inhibitor.

• Authors : Tsunoda, Takeshi¹ (AUTHOR); Furumura, Shunkichi² (AUTHOR); Yamazaki, Haruka² (AUTHOR)

• Source: Communications Chemistry. 1/13/2025, Vol. 8 Issue 1, p1-8. 8p.

Record details

Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL

• Authors : Lavinia Arseni; Gianluca Sigismondo; Haniyeh Yazdanparast

Subjects: Science

• Source: Nature Communications, Vol 16, Iss 1, Pp 1-16 (2025)

Record details

Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm

• Authors : Sabine Khalife-Hachem; Arnaud Pages; Elie Akoury

Subjects: Specialties of internal medicine; RC581-951

• Source: Blood Advances, Vol 9, Iss 4, Pp 793-796 (2025)

Record details

The Synergistic Effect of Reduced Graphene Oxide and Proteasome Inhibitor in the Induction of Apoptosis through Oxidative Stress in Breast Cancer Cell Lines.

• Authors : Krętowski, Rafał¹ (AUTHOR) ; Szynaka, Beata² (AUTHOR) ; Jabłońska-Trypuć, Agata³ (AUTHOR)

Subjects: *PROTEASOME inhibitors; *CANCER cells; *GRAPHENE oxide

• Source: International Journal of Molecular Sciences. May2024, Vol. 25 Issue 10, p5436. 23p.

Record details

Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma

• Authors : Ferguson, Ian D; Lin, Yu-Hsiu T; Lam, Christine

Subjects: Biochemistry and Cell Biology; Biological Sciences; Rare Diseases

• Source: Cell Chemical Biology. 29(8)

Record details

Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment.

• Authors : Jeon, Min Ji¹ (AUTHOR); Yu, Eun Sang¹ (AUTHOR); Kim, Dae Sik¹ (AUTHOR)

• Source: Scientific Reports. 11/5/2024, Vol. 14 Issue 1, p1-8. 8p.

Record details

Corrigendum: Proteasome inhibitor YSY01A abrogates constitutive STAT3 signaling via down-regulation of Gp130 and JAK2 in human A549 lung cancer cells

• Authors : Wei Huang; Xia Yuan; Ting Sun

Subjects: proteasome inhibitor; YSY01A; STAT3 signaling

• Source: Frontiers in Pharmacology, Vol 15 (2024)

Record details

First-Line Combination with Proteasome Inhibitor-Based Treatment and Zoledronic Acid Is Effective in Reducing Later Fractures in Multiple Myeloma Irrespective of Multiple Myeloma Bone Disease at Diagnosis.

• Authors : Eskelinen, Veera¹ (AUTHOR) ; Nivakoski, Elise¹ (AUTHOR) ; Launonen, Kirsi² (AUTHOR)

• Source: Hematology Reports. Sep2024, Vol. 16 Issue 3, p529-540. 12p.

Record details